Streptococcus Patents (Class 514/2.6)
-
Publication number: 20120003203Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases.Type: ApplicationFiled: September 10, 2009Publication date: January 5, 2012Inventors: Yaffa Mizrachi-Nebenzahl, Ron Dagan
-
Publication number: 20110305682Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases.Type: ApplicationFiled: September 10, 2009Publication date: December 15, 2011Applicant: Ben Gurion University of the Negev Research and Development AuthorityInventors: Yaffa Mizrachi-Nebenzahl, Ron Dagan
-
Publication number: 20110287040Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.Type: ApplicationFiled: May 23, 2011Publication date: November 24, 2011Inventors: Theodore E. Maione, Joseph Carozza, C. Dean Maglaris
-
Publication number: 20110280813Abstract: The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors.Type: ApplicationFiled: November 13, 2009Publication date: November 17, 2011Inventors: Alice Prince, Liang Tong
-
Publication number: 20110268703Abstract: A strain of Enterococcus mundtii has probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. An isolated nucleotide sequence codes for the antimicrobial peptide (peptide ST4SA). A process is also provided for the production of a peptide which comprises cultivating Enterococcus mundtii strain ST4SA in a nutrient medium under micro-aerophilic conditions at a temperature of between 10° C. and 45° C., until a recoverable quantity of the peptide is produced, and recovering the peptide. The isolated peptide may be used as an antimicrobial agent in a liquid formulation or a gel formulation as a topical treatment and may also be used as an antimicrobial agent following encapsulation in a polymer.Type: ApplicationFiled: April 26, 2011Publication date: November 3, 2011Inventors: Leon Milner Theodore Dicks, Svetoslav Dimitrov Todorov, Hendriette Knoetze, Marelize Brink
-
Publication number: 20110269670Abstract: The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates.Type: ApplicationFiled: September 11, 2009Publication date: November 3, 2011Inventors: Helen Connaris, Garry Taylor
-
Patent number: 8044022Abstract: Several species of bacteria capable of invasive infections, such as S. pyogenes, S. equi and P. multocida, contain hyaluronic acid (HA) in their capsules. Bacterial species such as Staphylococcus aureus and related Staphylococci have capsules that contain acidic polysaccharides. Bacterial capsule or bacterial surface binding peptides were synthesized and tested in a culture model of invasive bacterial infections, specifically translocation through polarized keratinocyte cultures. The peptides reduced the translocation of a variety of bacterial species, with a concomitant increase in bacterial internalization by the keratinocytes. In vivo, subcutaneous inoculation of encapsulated GAS treated with peptides delayed bacterial dissemination. In a mouse surgical wound model infected with S. aureus, treatment with peptides reduced the numbers of bacteria and inflammation at the wound site.Type: GrantFiled: June 8, 2006Date of Patent: October 25, 2011Inventors: Tadeusz Kolodka, Bernard T. Charlton, Wendy Johnson
-
Publication number: 20110245152Abstract: The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.Type: ApplicationFiled: September 28, 2007Publication date: October 6, 2011Inventors: Ahmed El-Meleigy Yousef, Zengguo He, Chunhua Yuan, Liwen Zhang, Duygu Kisla
-
Patent number: 8025890Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: May 16, 2006Date of Patent: September 27, 2011Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter InstituteInventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Publication number: 20110209228Abstract: The present invention provides peptides and analogs and derivatives thereof having antimicrobial activity at least against Streptococcus uberis for the treatment of a range of infectious disease mastitis, otitis externa, clostridial intestinal disease and respiratory disease.Type: ApplicationFiled: March 13, 2009Publication date: August 25, 2011Inventors: Benjamin Cocks, German Spangenberg, Jianghui Wang
-
Publication number: 20110207657Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.Type: ApplicationFiled: November 2, 2010Publication date: August 25, 2011Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Fengxia Qi, Jian He, Ian H. McHardy, Maxwell H. Anderson
-
Patent number: 8003602Abstract: This invention relates to a novel purified compound PM181104, of formula: of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present invention further relates to processes for the production of the novel antibacterial compound(s), to the production of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269), and to pharmaceutical compositions containing the novel compound(s) as an active ingredient and its/their use in medicines for treatment and prevention of diseases caused by bacterial infections.Type: GrantFiled: April 10, 2007Date of Patent: August 23, 2011Assignees: Piramal Life Sciences Limited, Council of Scientific and Industrial ResearchInventors: Girish Badrinath Mahajan, Saji David George, Prafull Vasant Ranadive, Prabhu Dutt Satyanarayan Mishra, Sreekumar Sankaranarayanan Eyyammadichiyil, Rajan Mukund Panshikar, Satish Namdeo Sawant, Sridevi Krishna, Meenakshi Sivakumar, Koteppa Pari, Becky Mary Thomas, Zarine Eruch Patel, Ram Vishwakarma, Chandrakant Govind Naik, Lisette D'Souza, Prabha Devi
-
Publication number: 20110201546Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.Type: ApplicationFiled: August 29, 2009Publication date: August 18, 2011Applicant: TARGANTA THERAPEUTICS CORP.Inventors: Dario Lehoux, Thomas R Parr, Gregory Moeck, Pierre Etienne
-
Patent number: 7989416Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: January 17, 2007Date of Patent: August 2, 2011Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Publication number: 20110143992Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.Type: ApplicationFiled: February 13, 2007Publication date: June 16, 2011Inventors: Dennis Taub, Vishwa Deep Dixit
-
Publication number: 20110105385Abstract: The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.Type: ApplicationFiled: May 15, 2009Publication date: May 5, 2011Inventors: Ruiliang Lu, Alessio Fasano
-
Publication number: 20110091494Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S.Type: ApplicationFiled: March 17, 2009Publication date: April 21, 2011Applicant: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing, Alexander Von Gabain
-
Publication number: 20110021415Abstract: The present invention relates to peptides comprising amino acids according to Formula I ((X)l(Y)m)n??(I) wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment of microbial infections.Type: ApplicationFiled: September 29, 2010Publication date: January 27, 2011Applicant: NOVABIOTICS LIMITEDInventor: DEBORAH O'NEIL
-
Publication number: 20110020216Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.Type: ApplicationFiled: June 11, 2008Publication date: January 27, 2011Inventors: David James Mooney, Omar abdel-Rahman Ali
-
Publication number: 20100331241Abstract: Novel bacteriocins and/or the novel lactic acid-producing strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.Type: ApplicationFiled: June 10, 2010Publication date: December 30, 2010Inventors: NORMAN J. STERN, EDWARD A. SVETOCH, BORIS V. ERUSLANOV, LARISA I. VOLODINA, YURI N. KOVALEV, TAMARA Y. KUDRYAVTSEVA, VLADIMIR V. PERELYGIN, VICTOR D. POKHILENKO, VLADIMIR P. LEVCHUK, VALERY N. BORZENKOV, OLGA E. SVETOCH, EUGENI V. MITSEVICH, IRINA P. MITSEVICH
-
Publication number: 20100323950Abstract: The present invention is directed to the use of the peptide compound Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: ApplicationFiled: September 9, 2008Publication date: December 23, 2010Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20100305027Abstract: Cyclic peptides having a random alternation of L-?-aminoacyl residues and aza-?3-aminoacyl residues and their uses.Type: ApplicationFiled: October 8, 2008Publication date: December 2, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES IInventors: Mathieu Laurencin, Celine Zatylny-Gaudin, Joel Henry, Michele Baudy Floc'H
-
Publication number: 20100286028Abstract: The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: ApplicationFiled: September 9, 2008Publication date: November 11, 2010Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20100286029Abstract: The present invention is directed to the use of the peptide compound Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: ApplicationFiled: September 9, 2008Publication date: November 11, 2010Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20100261638Abstract: The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), wherein: X1 denotes that the residue is Leu; Val; or Ile; X2 denotes that the residue is Leu; Val; or Ile; R1 represents an alkyl or heteroalkyl group, substituted by at least one hydroxyl substituent, and R2 represents hydrogen, or an alkyl or heteroalkyl group, optionally substituted by at least one hydroxyl substituent, or R1 and R2 taken together with the nitrogen atom represent a heterocyclic group having at least one hydroxyl substituent, wherein the heterocyclic group optionally further contains one or more heteroatoms; Z is an amino acid residue, —NR3R4, —NR5COR6, —NR5C(O)OR6; —NR5SOR6, NR5SO2R6; —NR5C(S)NR6R7, —NR5C(NR8)NR6R7, or —N?R9, where R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, or a group, optionally substituted, selected from alkyl, heteroalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, with the proviso that R9 is not hydrogen; and Y is —S— or —S(O)—.Type: ApplicationFiled: June 18, 2008Publication date: October 14, 2010Inventor: Sjoerd Nicolaas Wadman
-
Publication number: 20100247648Abstract: The invention relates to compositions comprising a compound based on the general formula (I) R1-Arg-R2—NH—CH(R3)—CH2—NH—R4??(I) The composition may be used to eliminate and/or reduce microorganisms such as bacteria, viruses, fungi and protozoa.Type: ApplicationFiled: March 8, 2010Publication date: September 30, 2010Applicant: Neobiotics ABInventors: Anders Grubb, Aftab Jasir, Claes Schalén, Franciszek Kasprzykowski, Regina Kasprzykowska